Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
6.
IEEE Pulse ; 12(3): 21-23, 2021.
Article in English | MEDLINE | ID: covidwho-1280250

ABSTRACT

In the wake of the COVID-19 pandemic, the need for rapid and accurate diagnostic testing across populations quickly became evident. In response, the National Institutes of Health (NIH) was determined not only to invest heavily in this area but to change the process by which grant proposals were reviewed and funded in order to spur faster development of viable technologies. The Rapid Acceleration of Diagnostics (RADx) initiative was designed to speed innovation, commercialization, and implementation of potential COVID-19 diagnostic technology. As part of this effort, the RADx Tech initiative focuses on the development, validation, and commercialization of innovative point-of-care, home-based, and clinical lab-based tests that can detect SARS-CoV-2. This effort was enabled through the NIH's National Institute of Biomedical Imaging and Bioengineering (NIBIB) Point-of-Care Technology Research Network (POCTRN).


Subject(s)
Biomedical Engineering/economics , COVID-19 Testing/economics , COVID-19 , National Institutes of Health (U.S.)/economics , Pandemics , Point-of-Care Systems/economics , SARS-CoV-2 , Biomedical Engineering/trends , COVID-19/diagnosis , COVID-19/economics , COVID-19/epidemiology , Humans , United States
10.
Cancer Discov ; 11(3): 524, 2021 03.
Article in English | MEDLINE | ID: covidwho-1040977

ABSTRACT

The federal spending bill enacted by the U.S. Congress in December for fiscal year 2021 totals $1.4 trillion, plus another $900 billion in emergency COVID-19 relief funding. The $1.4 trillion includes budget increases for the NIH, NCI, and FDA that help the agencies keep pace with inflation. Research advocates say more than $10 billion in emergency supplemental funds for the NIH is urgently needed to support medical research affected by the COVID-19 pandemic.


Subject(s)
Biomedical Research/legislation & jurisprudence , Federal Government , Health Policy , Neoplasms/therapy , Research Support as Topic , Biomedical Research/economics , COVID-19/economics , COVID-19 Vaccines/economics , Humans , Medical Oncology/organization & administration , National Cancer Institute (U.S.)/economics , National Institutes of Health (U.S.)/economics , Neoplasms/economics , Societies, Medical , United States , United States Food and Drug Administration/economics
11.
Nature ; 581(7808): 252-255, 2020 05.
Article in English | MEDLINE | ID: covidwho-831180

Subject(s)
Antiviral Agents/pharmacology , Betacoronavirus/chemistry , Betacoronavirus/immunology , Drug Design , Viral Proteins/antagonists & inhibitors , Viral Proteins/chemistry , Viral Vaccines , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/pharmacology , Adenosine Monophosphate/therapeutic use , Alanine/analogs & derivatives , Alanine/pharmacology , Alanine/therapeutic use , Angiotensin-Converting Enzyme 2 , Animals , Antiviral Agents/chemistry , Azoles/pharmacology , Betacoronavirus/drug effects , Betacoronavirus/enzymology , COVID-19 Vaccines , China , Coronavirus 3C Proteases , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Coronavirus Papain-Like Proteases , Coronavirus RNA-Dependent RNA Polymerase , Cryoelectron Microscopy , Crystallization , Crystallography, X-Ray , Cysteine Endopeptidases/chemistry , Cysteine Endopeptidases/metabolism , Drug Evaluation, Preclinical , Germany , High-Throughput Screening Assays , Humans , Isoindoles , Mice , National Institutes of Health (U.S.)/economics , National Institutes of Health (U.S.)/organization & administration , Organoselenium Compounds/pharmacology , Peptidyl-Dipeptidase A/chemistry , Peptidyl-Dipeptidase A/metabolism , Protease Inhibitors/pharmacology , RNA-Dependent RNA Polymerase/antagonists & inhibitors , RNA-Dependent RNA Polymerase/chemistry , RNA-Dependent RNA Polymerase/metabolism , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/chemistry , Spike Glycoprotein, Coronavirus/metabolism , Synchrotrons , Time Factors , United Kingdom , United States , Viral Nonstructural Proteins/antagonists & inhibitors , Viral Nonstructural Proteins/chemistry , Viral Nonstructural Proteins/metabolism , Viral Proteins/immunology
12.
Am J Clin Nutr ; 112(3): 721-769, 2020 09 01.
Article in English | MEDLINE | ID: covidwho-657560

ABSTRACT

BACKGROUND: The US faces remarkable food and nutrition challenges. A new federal effort to strengthen and coordinate nutrition research could rapidly generate the evidence base needed to address these multiple national challenges. However, the relevant characteristics of such an effort have been uncertain. OBJECTIVES: Our aim was to provide an objective, informative summary of 1) the mounting diet-related health burdens facing our nation and corresponding economic, health equity, national security, and sustainability implications; 2) the current federal nutrition research landscape and existing mechanisms for its coordination; 3) the opportunities for and potential impact of new fundamental, clinical, public health, food and agricultural, and translational scientific discoveries; and 4) the various options for further strengthening and coordinating federal nutrition research, including corresponding advantages, disadvantages, and potential executive and legislative considerations. METHODS: We reviewed government and other published documents on federal nutrition research; held various discussions with expert groups, advocacy organizations, and scientific societies; and held in-person or phone meetings with >50 federal staff in executive and legislative roles, as well as with a variety of other stakeholders in academic, industry, and nongovernment organizations. RESULTS: Stark national nutrition challenges were identified. More Americans are sick than are healthy, largely from rising diet-related illnesses. These conditions create tremendous strains on productivity, health care costs, health disparities, government budgets, US economic competitiveness, and military readiness. The coronavirus disease 2019 (COVID-19) outbreak has further laid bare these strains, including food insecurity, major diet-related comorbidities for poor outcomes from COVID-19 such as diabetes, hypertension, and obesity, and insufficient surveillance on and coordination of our food system. More than 10 federal departments and agencies currently invest in critical nutrition research, yet with relatively flat investments over several decades. Coordination also remains suboptimal, documented by multiple governmental reports over 50 years. Greater harmonization and expansion of federal investment in nutrition science, not a silo-ing or rearrangement of existing investments, has tremendous potential to generate new discoveries to improve and sustain the health of all Americans. Two identified key strategies to achieve this were as follows: 1) a new authority for robust cross-governmental coordination of nutrition research and other nutrition-related policy and 2) strengthened authority, investment, and coordination for nutrition research within the NIH. These strategies were found to be complementary, together catalyzing important new science, partnerships, coordination, and returns on investment. Additional complementary actions to accelerate federal nutrition research were identified at the USDA. CONCLUSIONS: The need and opportunities for strengthened federal nutrition research are clear, with specific identified options to help create the new leadership, strategic planning, coordination, and investment the nation requires to address the multiple nutrition-related challenges and grasp the opportunities before us.


Subject(s)
Coronavirus Infections/complications , Nutrition Disorders/complications , Nutritional Physiological Phenomena , Pneumonia, Viral/complications , Research/standards , COVID-19 , Cost of Illness , Health Care Costs , Healthcare Disparities/economics , Humans , Military Personnel , National Institutes of Health (U.S.)/economics , Nutrition Disorders/economics , Nutrition Disorders/epidemiology , Pandemics , United States/epidemiology , United States Department of Agriculture/economics , United States Dept. of Health and Human Services/economics
SELECTION OF CITATIONS
SEARCH DETAIL